Publications by authors named "V J Stecher"
Introduction: The serendipitous discovery of sildenafil (Viagra [sildenafil citrate]) as a treatment for erectile dysfunction (ED) is one of the most fascinating drug development stories of our time. When sildenafil was approved by the U.S.
View Article and Find Full Text PDFErectile dysfunction (ED), which worldwide is likely to affect in excess of 300 million men by 2025, is often either untreated or insufficiently treated. It can be a prelude to other serious illnesses and may be a cause or consequence of depression in affected individuals. Among men younger than 60 years of age, ED can be a robust early-stage indicator of vascular disease and type 2 diabetes.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates why some men with erectile dysfunction (ED) report improvement in sexual function even when given placebo in sildenafil trials, highlighting the significance of demographic factors and co-morbidities.
- It analyzed data from 4,360 men, finding that 13.5% responded positively to placebo, with higher likelihoods associated with being younger, black, having mild ED, and lacking diabetes.
- Key insights indicate that as the duration of ED increases, the likelihood of a placebo response decreases, while adverse event rates remained similar regardless of response status.
Background: Patient-reported outcomes, such as the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) index, are essential for successful evaluation and treatment of patients with erectile dysfunction.
Aim: To enrich interpretation of the EDITS index score and to complement the existing 0 to 100 scoring.
Methods: This supplemental analysis evaluated EDITS questionnaire data (11 items; index score range = 0-100; higher scores indicate more treatment satisfaction) after completion of an 8-week double-blinded trial of 279 men 18 to 65 years old with erectile dysfunction randomized to sildenafil 100 mg, sildenafil 50 mg, or placebo.
Aims: To evaluate the relationship of comorbidities (cardiovascular disease [CVD], diabetes mellitus [DM] and depression) with erectile dysfunction (ED) and age using real-world claims data from 48 million men in the United States.
Methods: This was a cross-sectional, non-interventional study in men aged ≥18 years using data from the Truven Health MarketScan and Medicare Supplemental Research Databases from January 2010 to December 2015, with an observational period of January 2011 to December 2014 to allow for 12 months pre- and post-index. Comorbidity rate was compared between ED and non-ED groups by age using the χ (bivariate) test.